The EBIN phase 2 trial evaluated whether targeted therapy induction followed by immunotherapy is superior to immunotherapy alone in advanced BRAFV600-mutant melanoma.
No significant difference in progression-free survival (PFS) was observed between the two strategies.
The induction group experienced higher rates of severe (grade 3-5) treatment-related adverse events.
Current data do not support routine use of targeted therapy induction in unselected patients with BRAFV600-mutant metastatic melanoma.
